First patients to test new oral cancer drug targeting specific mutations

NCT ID NCT06983743

Recruiting now Disease control Sponsor: Erasca, Inc. Source: ClinicalTrials.gov ↗

Summary

This is the first study in humans testing a new oral cancer drug called ERAS-0015. Researchers want to find the safest dose and see if it helps control advanced solid tumors that have spread and have specific genetic changes. The drug will be tested alone and combined with other treatments in about 200 patients who have run out of standard treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Florida Cancer Specalists
RECRUITING

Sarasota, Florida, 34232, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Texas at Tyler
RECRUITING

Tyler, Texas, 75701, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC SOLID TUMORS